Item 5.07. Submission of Matters to a Vote of Security Holders.





On June 2, 2021, ANI Pharmaceuticals, Inc. (the "Company") held its 2021 annual
meeting of stockholders (the "Annual Meeting"). The following sets forth the
matters that were voted upon by the Company's stockholders at the Annual Meeting
and the voting results for such matters. These matters are described in more
detail in the Company's definitive proxy statement on Schedule 14A filed with
the Securities and Exchange Commission on April 29, 2021 (the "Proxy
Statement").

1. The Company's stockholders voted to elect the following directors, each to

serve until his or her successor has been duly elected and qualified or until


    his or her earlier resignation or removal. The final voting results are as
    follows:




               Nominee                      For          Against        Abstentions      Broker Non-Votes
1. Robert E. Brown, Jr.                   9,466,522        325,176         

   3,376               797,905
2. Thomas Haughey                         9,534,467        257,199             3,408               797,905
3. Nikhil Lalwani                         9,655,278        136,331             3,465               797,905

4. David B. Nash, M.D., M.B.A.            9,409,937        381,762         

   3,375               797,905
5. Antonia R. Pera                        9,656,007        135,634             3,433               797,905
6. Jeanne A. Thoma                        9,652,137        139,542             3,395               797,905
7. Patrick D. Walsh                       9,392,837        398,827             3,410               797,905

2. The Company's stockholders approved, on a non-binding advisory basis, the

compensation of the Company's named executive officers, as described in the

Proxy Statement. The final voting results are as follows:






    For          Against       Abstentions      Broker Non-Votes
  9,417,485       328,111            49,478               797,905

3. The Company's stockholders ratified the appointment of EisnerAmper LLP as the

Company's independent registered public accounting firm for the year ending

December 31, 2021. The final voting results are as follows:




    For          Against       Abstentions       Broker Non-Votes
  10,546,523       42,147             4,309                     --

4. The Company's stockholders approved in connection with the Company's pending

acquisition of Novitium Pharma LLC ("Novitium"), the issuances of

(a) 2,466,667 shares of common stock to certain members of Novitium and

(b) 25,000 shares of Series A Convertible Preferred Stock to Ampersand 2020


    Limited Partnership. The final voting results are as follows:




    For         Against       Abstentions      Broker Non-Votes
  9,727,248       57,285            10,541               797,905

Item 7.01. Regulation FD Disclosure.





On June 4, 2021, the Company posted an investor presentation to the Investor
Relations section of its website at www.anipharmaceuticals.com in connection
with a presentation by its executives at an investor conference. A copy of the
investor presentation is being furnished as Exhibit 99.1 to this Current Report
on Form 8-K.



The information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, are furnished and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended or the Exchange Act, except as shall be expressly set forth by
specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.





Exhibit      Description

  99.1         Investor Presentation - June 2021.
104          Cover Page Interactive Data File (embedded within the inline XBRL
             document).

© Edgar Online, source Glimpses